H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $136 from $138 and keeps a Buy rating on the shares following the Q2 report. The firm factored in increased operating expenses moving forward. BioNTech’s patent litigation settlement with CureVac and GSK is “incrementally positive,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s Latest Clinical Study: A New Hope for Advanced Breast Cancer Treatment
- BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer?
- BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer
- BioNTech’s Promising Lung Cancer Study: A Potential Game-Changer in Oncology
- BioNTech Settles Patent Disputes with CureVac and GSK